113 related articles for article (PubMed ID: 26667599)
1. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Yiu ZZ; Ali FR; Griffiths CE
Clin Exp Dermatol; 2016 Jun; 41(4):407-9. PubMed ID: 26667599
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
3. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
4. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
5. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
6. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Adachi T; Hiraoka A; Okazaki H; Nagamatsu K; Izumoto H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Yamago H; Iwasaki R; Suga Y; Mori K; Miyata H; Tsubouchi E; Ninomiya T; Michitaka K
Clin J Gastroenterol; 2020 Oct; 13(5):891-895. PubMed ID: 32468502
[TBL] [Abstract][Full Text] [Related]
7. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Francini E; Mazzaroppi S; Fiaschi AI; Petrioli R; Laera L; Roviello G; Pira T; Pellicelli AM; Bianco V
J Am Geriatr Soc; 2014 Nov; 62(11):2204-5. PubMed ID: 25413190
[No Abstract] [Full Text] [Related]
8. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
[No Abstract] [Full Text] [Related]
9. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
10. Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
Antoniou EA; Koutsounas I; Damaskos C; Koutsounas S
In Vivo; 2016 09-10; 30(5):677-80. PubMed ID: 27566090
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
12. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Nakagawa T; Chubachi S
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1107-9. PubMed ID: 26469170
[TBL] [Abstract][Full Text] [Related]
14. Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Huang YH; Siao FY; Yen HH
Gastroenterology; 2015 Aug; 149(2):e12-3. PubMed ID: 26123559
[No Abstract] [Full Text] [Related]
15. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
[TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
18. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
20. Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.
Kwon SY; Kim DY; Min JJ; Bae WK
Clin Nucl Med; 2018 Jan; 43(1):31-32. PubMed ID: 29112010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
